Pulse Biosciences Inc. (6L8)
XSTU 
Summary
6L8 Chart
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript
Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago.
Pulse Biosciences Inc. (6L8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pulse Biosciences Inc. ever had a stock split?
Pulse Biosciences Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Paul Arthur LaViolette CEO | XSTU Exchange | US74587B1017 ISIN |
| US Country | 75 Employees | - Last Dividend | - Last Split | 18 May 2016 IPO Date |
Overview
Pulse Biosciences, Inc. is a pioneering bioelectric medicine company, previously known as Electroblate, Inc. until its name change in December 2015. Founded in 2014, the company has quickly positioned itself at the forefront of medical technology innovation with its headquarters in Hayward, California. The company's core mission revolves around developing novel therapeutic devices that leverage its unique Nano-Pulse Stimulation (NPS) technology. This technology represents a significant advancement in treating a broad spectrum of medical conditions by delivering nano-second pulses of electrical energy directed at targeted cells. Unlike traditional methods, this approach ensures the non-thermal destruction of cells while preserving adjacent non-cellular tissues, marking a new era in precision medicine.
Products and Services
The cornerstone of Pulse Biosciences’ offering is the CellFX System. This platform embodies the practical application of Nano-Pulse Stimulation technology in clinical settings. Details of the product include:
- CellFX System: A tunable, software-enabled, console-based platform designed for precision. It harnesses the power of nano-second duration pulses of electrical energy. The system's unique capability to non-thermally clear targeted cells without damaging adjacent non-cellular tissue addresses a vast array of medical conditions. Its versatility and efficacy position it as a revolutionary tool in the field of bioelectric medicine.
Contact Information
